#### February 2012

#### RESULTS FOR THE YEAR ENDED 31 DECEMBER 2011



#### Devro: The collagen casing company

#### Global Leader

- One of the world's leading providers of collagen casings to the growing processed meats sector
- Provides technical support to food manufacturers

#### Global Operations

- Over 2,000 staff across the world
- 5 manufacturing sites in Scotland, Australia, the Czech Republic and the USA

#### Collagen

- Main raw material taken from the hide of carefully selected animals certified for food use
- A complex naturally-occurring polymer with unique characteristics

#### **Technology**

- Significant investment in the latest processes funded from internal cash generation.
- Improved manufacturing performance and increased capacity



## Devro: Four years of growth and investment






#### Devro: 2011 Highlights



SIMON WEBB
GROUP FINANCE DIRECTOR



#### Financial Highlights – continuing operations





## Financial Highlights

#### For the year ended 31 December 2011

Continuing Operations	2011 £m	2010 £m	Increase %
Sales	227.7	213.6	+ 6.6%
EBIT	42.7	37.0	+ 15.5%
PBT pre-exceptionals	43.0	35.2	+ 22.4%
Earnings per share pre-exceptionals	20.8p	17.0p	+ 22.4%
Dividend	8.0p	7.0p	+ 14.3%
Net debt	22.7	12.2	
Gearing	16.2%	8.0%	
Discontinued operation PBT	0.0	1.2	



# Financial Highlights Impact of Devro GmbH sale

Continuing + discontinued operations	2011 Actual	2010 Actual
Sales £m	244.1	237.0
EBIT £m	42.7	38.2

Devro GmbH – discontinued operation	2011 Actual	2010 Actual
Sales £m	16.4	23.4
EBIT £m	0.0	1.2

Continuing operations (excluding discontinued operation)	2011 Actual	2010 Actual	% Change
Sales £m	227.7	213.6	6.6%
EBIT £m	42.7	37.0	15.5%



#### Income statement

#### For the year ended 31 December 2011

Continuing Operations	2011 £m	2010 £m	Increase %
Sales	227.7	213.6	6.6%
Operating profit	42.7	37.0	15.5%
Operating margin	18.7%	17.3%	
Exceptional item	-	18.8	
Net finance income/ (costs)	(0.9)	(0.7)	
Net pension finance income/ (costs)	1.2	(1.1)	
Profit before tax	43.0	54.0	
Tax	(8.8)	(12.5)	
Profit for the period – continuing operations	34.2	41.5	
Discontinued operation	(0.0)	0.7	
Profit after tax including discontinued operation	34.2	42.2	



# Regional sales by destination 2011


(Change vs. 2010)

Paul 476			Cas	-	- 0.00
	2011 £'m	Volume %	Price/Mix %	Exchange %	Total %
Europe	8.5	3.3	3.2	1.4	7.9
Americas	0.8	5.1	0.0	(3.4)	1.7
Asia/Pacific	4.8	(0.6)	3.2	5.8	8.4
Total	14.1	3.0	2.2	1.4	6.6



## EBIT bridge

#### December 2010 EBIT to December 2011 EBIT



#### A tale of two halves

		H1			H2			Total	
	2011	2010	%	2011	2010	%	2011	2010	%
Sales £m	107.1	104.6	2.4%	120.6	109.0	10.6%	227.7	213.6	6.6%
Operating profit before exceptional items £m	19.5	17.5	11.6%	23.2	19.5	19.0%	42.7	37.0	15.5%
% Margin	18.2%	16.7%		19.2%	17.9%		18.7%	17.3%	

• Second half sales gathered momentum



## Debt

	2011	2010
Net debt	£22.7m	£12.2m
Gearing	16.2%	8.0%

- Significant investments in capital
- Underlying operating cash flow is strong



#### Pensions

#### **Group Defined Benefit Pension Schemes**

	2011	2010
	£m	£m
Fair value of scheme assets	196.6	198.5
Present value of scheme liabilities	(242.8)	(211.9)
Net pension liabilities	(46.2)	(13.4)


Rise in pension deficit due to decrease in discount rates (UK schemes 2011 - 4.7%; 2010 - 5.4%)

	2011	2010
	£m	£m
Interest income/(costs)	1.2	(1.1)

• Interest income reflects the expected return on assets offset by interest on liabilities. It will be an expense of £1.2m in 2012.



#### Tax




- Investment incentive in Czech Republic
- Lower group tax rate expected to continue until at least 2015




2010 effective tax rate is before exceptionals

## **Key Performance Indicators**




Return on capital employed (ROCE)
Operating profit before exceptional items/average capital employed %





Operating cash flow Cash generated from operations £m



PETER PAGE
CHIEF EXECUTIVE OFFICER



#### Our Three Part Strategy

#### Revenue Growth

- Gut replacement in established markets
- Increased demand in emerging markets
- Pricing and value for customers

Earnings Growth & Improving Return on Capital

# Manufacturing Efficiency

- Maximise productivity of existing assets
- New capacity is lowest unit cost technology
- Reducing costs

#### **Collagen Research & Development**

- Differentiated products
- Modern processes improve efficiency
  - Creating new opportunities




#### Revenue growth achieved

- Edible collagen volumes 4.6% higher
- Edible collagen revenues 9% higher
- Select 5% of edible collagen revenues
- Sales revenues in Japan 32% higher than in 2010
- Select 29.1% of sales in Germany
- Average price per unit sold 4.2% higher
- Following disposal of Devro GmbH, edible collagen casings and gel account for 88% of sales revenue



## Select casings becoming established .....


Demonstrates that product differentiation is possible and profitable





## ..... as Grade A sheep gut availability declines

COMBINED NZ / AUSTRALIA / UK
LAMB / SHEEP SLAUGHTER (rolling 12 months total number of animals)





Source: Government statistics

## Opportunity for Select continues to grow





#### Emerging markets – volume growth

# Latin America & Mexico

- Volume +6.4%
- Revenue (LC) +14%
- Improved price mix
- Sales through distributors

# Eastern Europe & Russia

- Volume +21%
- Revenue (LC) +23%
- Combination of Devro sales & distributors

#### **South East Asia**

- Volume +16.8%
- Revenue (LC) +20%
- Sales through distributors
- Stronger Hong Kong team

#### China

- Volume/Revenue temporary decline
- Working to broaden customer base
- Beijing office established



## Setting the standard worldwide

- FS 22000: the new single global food safety standard
- Combines ISO 22000: 2005 and ISO/TS 22002: 2009
- Managed by Foundation for Food Safety Certification





Only one collagen casings manufacturer has accreditation at all manufacturing sites - Devro






## Manufacturing and capacity investments

- Total volumes produced same as 2010
- Capacity installed and ready to operate from January 2012 equivalent to 4% of 2010 output.
- Installations in 2012 equivalent to 8% of 2010
- Installations in 2013 equivalent to 8% of 2010
- Three fold benefit:
  - Lower unit costs
  - Stepped additions of capacity
  - Broader product range




## Investing in manufacturing capacity and efficiency





## Investing capital for growth





#### Market situation

- Demand for collagen casings continues to grow
- Customers' ingredient costs may benefit from reducing wheat prices, corn prices constant, soya prices constant
- Sheep gut availability constrained
- Hog gut availability sufficient and prices lower than 2010
- Hide availability constant from key suppliers but global market is changing



#### 2012 Outlook favourable

- Demand for edible collagen continues to grow
- Further work to establish sales of Select
- Margins maintained
- Additional manufacturing capacity from UK and USA
- Return on capital employed target of 20%



